Entrada Therapeutics Inc
NASDAQ:TRDA
Entrada Therapeutics Inc
Total Receivables
Entrada Therapeutics Inc
Total Receivables Peer Comparison
Competitive Total Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Entrada Therapeutics Inc
NASDAQ:TRDA
|
Total Receivables
$5.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Total Receivables
$11.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
16%
|
CAGR 10-Years
10%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Receivables
$4.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Receivables
$6.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Receivables
$1.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
33%
|
CAGR 10-Years
40%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Receivables
$5.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
See Also
What is Entrada Therapeutics Inc's Total Receivables?
Total Receivables
5.9m
USD
Based on the financial report for Dec 31, 2023, Entrada Therapeutics Inc's Total Receivables amounts to 5.9m USD.